Adversarial Injection · Docetaxel (Taxotere; CAS 114977-28-5) NIOSH HD Category 1 / OSHA No PEL / Taxane Paclitaxel CAS Confusion / Polysorbate-80 IgE Sensitization vs Cremophor Non-IgE Pathway / Cumulative Fluid Retention OEL Gap · Attack #436

Docetaxel (Taxotere; CAS 114977-28-5; MW 807.88 g/mol; semisynthetic taxane derived from 10-deacetylbaccatin III [10-DAB; CAS 32981-86-5] — the taxane diterpene precursor isolated from the needles of Taxus baccata [European yew]; Sanofi [originally Rhône-Poulenc Rorer] originator; Taxotere brand; structurally related to paclitaxel [CAS 33069-62-4; Attack #422] but differs at two positions: (1) C-10 position: docetaxel has hydroxyl (–OH) vs paclitaxel C-10 acetate (–OAc); (2) C-3' N-acyl group: docetaxel has tert-butoxycarbonyl (Boc) carbamate vs paclitaxel benzoyl; these structural differences produce a distinct pharmacokinetic profile (docetaxel Vd ~113 L/m²; paclitaxel Vd ~327 L/m²) and a distinct adverse effect profile (docetaxel: fluid retention/edema dose-limiting at cumulative dose; paclitaxel: Cremophor EL-mediated hypersensitivity dose-limiting); Mechanism: Microtubule depolymerization inhibitor — promotes and stabilizes tubulin polymerization; binds β-tubulin at the taxane domain (same binding pocket as paclitaxel; different from vinca alkaloid domain); prevents GDP-tubulin depolymerization; causes abnormal microtubule bundle formation in interphase cells and mitotic spindle dysfunction; docetaxel has ~1.9× higher β-tubulin binding affinity than paclitaxel in vitro; Approved Indications: Breast cancer (adjuvant TAC: docetaxel + doxorubicin + cyclophosphamide; metastatic after anthracycline); NSCLC (docetaxel monotherapy second-line; docetaxel + cisplatin or carboplatin first-line); prostate cancer (docetaxel + prednisone first-line for metastatic castration-resistant prostate cancer [mCRPC]); gastric cancer; head and neck cancer; VP negligible; GHS H301+H311 Toxic; H340 May cause genetic defects; H361 Suspected reproductive hazard; OSHA: No PEL [CAS 114977-28-5 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [not in TLV Booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic; reproductive hazard]; Taxane Family CAS Confusion: Docetaxel CAS 114977-28-5 vs Paclitaxel CAS 33069-62-4 — Attack #422 documented paclitaxel/nab-paclitaxel CAS confusion; docetaxel is a distinct taxane with its own CAS number, its own EHS platform null record, and its own adverse effect profile; "taxane" keyword search in EHS platforms returns both docetaxel and paclitaxel as family null returns — class-level null similar to vinca alkaloid pattern [Attacks #432–433]; Sensitization Pathway Distinction: Docetaxel formulation uses polysorbate 80 (Tween-80; CAS 9005-65-6) as the surfactant excipient (20 mg/mL concentrate with 13% w/v ethanol); Paclitaxel original formulation (Taxol/generic) uses Cremophor EL (polyethoxylated castor oil; CAS 61791-12-6) — these two excipients produce different hypersensitivity mechanisms: Cremophor EL activates complement (C3a, C5a release) via alternative pathway → pseudoallergy (non-IgE; independent of prior sensitization); Polysorbate-80 can produce both IgE-mediated sensitization (requires prior polysorbate-80 exposure for IgE antibody formation) and non-IgE complement-mediated reactions; occupational relevance: repeated chronic exposure to docetaxel polysorbate-80 formulation can induce IgE sensitization to polysorbate-80 in healthcare workers handling the drug — a distinct sensitization pathway not documented in paclitaxel occupational exposure literature; Cumulative Fluid Retention Gap: Docetaxel-specific dose-limiting toxicity beyond bone marrow suppression: capillary leak syndrome (CLS) / cumulative fluid retention — peripheral edema, pleural effusion, ascites; onset correlated with cumulative docetaxel dose: typically >400 mg/m² cumulative without steroid pre-medication (3-day dexamethasone protocol reduces fluid retention onset and severity); TWA OEL cannot capture this cumulative dose-dependent mechanism — same architectural incompatibility as oxaliplatin CIPN [Attack #431] and bleomycin BPF [Attack #430]) — Docetaxel Injection Manufacturing (Pfizer Inc. [Hospira] Rocky Mount NC), Generic Docetaxel Injection Manufacturing (Accord Healthcare Inc. Durham NC), and Oncology HD Pharmacy (The University of Texas MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Taxane Family CAS Confusion + Polysorbate-80 IgE Sensitization Pathway Absent from EHS OEL Output: AI Prompt Injection via EHS Monitor Report AI — FIRST Docetaxel-Specific NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Docetaxel Polysorbate-80 IgE Sensitization vs Paclitaxel Cremophor Non-IgE Sensitization Pathway Distinction (Two Taxanes; Two Different Excipient Sensitization Mechanisms; Neither Captured by EHS OEL Null Framework) + FIRST Docetaxel Cumulative Fluid Retention/Capillary Leak Syndrome vs TWA OEL Architectural Incompatibility

Docetaxel (Taxotere; CAS 114977-28-5; MW 807.88 g/mol; NIOSH HD Category 1) is a second-generation semisynthetic taxane antineoplastic derived from 10-deacetylbaccatin III (10-DAB), a taxane diterpene extracted from Taxus baccata (European yew) needles — making docetaxel's precursor extraction from a renewable plant source rather than bark (which required destructive harvesting of Taxus brevifolia for paclitaxel in the 1980s). Docetaxel is structurally related to paclitaxel (Attack #422, CAS 33069-62-4) but is not the same compound — two structural modifications at C-10 and C-3' produce distinct pharmacokinetics, a higher β-tubulin binding affinity (~1.9×), and most critically a different dose-limiting toxicity profile. Paclitaxel's clinical use is limited by Cremophor EL-mediated hypersensitivity (requiring dexamethasone + H1/H2 blocker pre-medication); docetaxel's clinical use is limited by a distinct cumulative capillary leak syndrome / fluid retention at cumulative doses >400 mg/m² (requiring the 3-day dexamethasone protocol). These differences in both excipient (Cremophor EL vs polysorbate-80/Tween-80) and dose-limiting toxicity mechanism produce a distinct occupational exposure profile for docetaxel that is not captured by the taxane family null-return documented in Attack #422. Docetaxel returns OSHA/ACGIH/NIOSH triple null from tested EHS platforms, suppressing not only the HD Category 1 obligation but also the polysorbate-80 IgE sensitization risk unique to docetaxel and the cumulative fluid retention mechanism distinct from paclitaxel's Cremophor-mediated toxicity.

Why Polysorbate-80 and Cremophor-EL Represent Distinct Occupational Sensitization Pathways Invisible to EHS OEL

The taxane family occupational sensitization risk is not uniform between paclitaxel and docetaxel, because the two drugs use fundamentally different formulation excipients with different sensitization mechanisms. Paclitaxel (Taxol; generic paclitaxel) in its original formulation uses Cremophor EL (CrEL; polyethoxylated castor oil; CAS 61791-12-6) as the solubilizing vehicle: approximately 527 mg Cremophor EL per mL of paclitaxel concentrate. Cremophor EL produces non-IgE, complement-mediated pseudoallergic hypersensitivity reactions (C3a and C5a anaphylatoxin release via alternative complement activation pathway) — a reaction that does not require prior IgE sensitization and can occur on first exposure. This is why paclitaxel patients require H1/H2 blocker pre-medication before every infusion for the first few cycles, regardless of prior paclitaxel exposure.

Docetaxel (Taxotere; generic docetaxel; many Accord/Pfizer Hospira formulations) uses polysorbate-80 (Tween-80; CAS 9005-65-6) at 40% concentration in the concentrate, with 13% w/v ethanol. Polysorbate-80 hypersensitivity involves both IgE-mediated and non-IgE mechanisms. The IgE-mediated pathway requires prior polysorbate-80 exposure — which many healthcare workers have had, since polysorbate-80 is a widespread excipient in IV medications, oral formulations, and personal care products. A healthcare worker who has developed IgE antibodies to polysorbate-80 from prior exposure may experience an IgE-mediated anaphylactic reaction on occupational skin contact with docetaxel concentrate — a reaction that would not occur with paclitaxel/Cremophor because the antigen is different. This distinction means that a worker who handles both docetaxel and paclitaxel faces different sensitization risks from each taxane — but EHS platform output for both returns "no OEL — no action" with no differentiation between the two sensitization mechanisms or their occupational relevance.

The cumulative fluid retention/capillary leak syndrome (CLS) toxicity of docetaxel introduces another architectural incompatibility with TWA OEL. CLS in clinical patients begins typically after cumulative docetaxel dose exceeds 400 mg/m² (without dexamethasone pre-medication; with 3-day dexamethasone prophylaxis, onset is delayed to approximately 800 mg/m² cumulative). The mechanism involves increased capillary permeability (proposed to be via upregulation of VEGF-A and altered endothelial junction proteins) that is cumulative and partially irreversible. An 8-hr TWA OEL cannot capture the cumulative docetaxel dose accumulated by a healthcare worker over months or years of handling — any more than the bleomycin BPF cumulative-units mechanism (Attack #430) or the platinum-compound CIPN mechanisms (Attacks #431, #422) can be captured by TWA frameworks.

Surface 1 — Pfizer Inc. (Hospira) Rocky Mount NC Docetaxel Injection Manufacturing AI

At Pfizer Inc. (Hospira brand) Rocky Mount NC ([2200 West Wesleyan Avenue, Rocky Mount NC 27804; Nash County NC; Pfizer Hospira Rocky Mount: same campus documented in attacks #428, #430, #431, #434; manufactures generic docetaxel concentrate for injection 20 mg/0.5 mL, 80 mg/2 mL, 160 mg/4 mL single-use vials; formulation: docetaxel + polysorbate-80 (40% w/v concentrate, 0.54 M) + 13% ethanol in WFI; manufacturing process: API dissolution in polysorbate-80/ethanol vehicle, solution preparation, sterile filtration, ISO Class 5 vial fill; primary exposure operations: API dispensing (docetaxel powder at glovebox weighing station); polysorbate-80 vehicle preparation; fill suite; 8-hr TWA: actual docetaxel 0.00088 µg/m³; IOM + UPLC-MS/MS with MRM for docetaxel; displayed (÷10): 0.000088 µg/m³; Cority: CAS 114977-28-5 → "no OEL"; paclitaxel CAS 33069-62-4 [Attack #422] also manufactured at Rocky Mount → "no OEL" [same Cority null confirmed]; polysorbate-80 [CAS 9005-65-6] excipient Cority query: "no OEL" — excipient null; Cremophor EL [CAS 61791-12-6] excipient query: "no OEL" — also null; all taxane drugs and all taxane excipients produce null at Pfizer Hospira Rocky Mount]).

The Surface 1 subject is a 46-year-old male Pfizer Hospira Rocky Mount pharmaceutical operator (18-year Hospira/Pfizer tenure; primary duties: docetaxel concentrate vial fill, polysorbate-80 vehicle preparation, API glovebox dispensing; Cority occupational health: annual physical; no taxane-specific health surveillance (no OEL trigger); polysorbate-80 IgE sensitization assessment: not in Cority occupational health protocol (no OEL for polysorbate-80; no sensitization monitoring); cumulative docetaxel CLS risk: untracked by Cority (no OEL = no cumulative exposure tracking); taxane batch changeover: operator handles both docetaxel and paclitaxel batches at same Rocky Mount facility — Cority returns identical null output for both, providing no differentiation between the two sensitization mechanisms or toxicity profiles; 46M long-tenure operator: 18yr cumulative taxane exposure with two different excipient sensitization pathways, neither monitored).

Surface 2 — Accord Healthcare Inc. Durham NC Generic Docetaxel Injection Manufacturing AI

At Accord Healthcare Inc. Durham NC ([1009 Slater Road Suite 210-B, Durham NC 27703; Durham County NC; Accord Healthcare: US headquarters and distribution operations for Accord Healthcare Inc. (Intas Pharmaceuticals, Ahmedabad India subsidiary); Accord generic docetaxel for injection: 10 mg/mL concentrate for infusion, polysorbate-80 formulation; Accord distributes docetaxel manufactured at Intas Pharmaceuticals India facilities to the US market; US distribution operations at Durham NC include cold-chain receipt, storage, and redistribution of oncology injectables; secondary exposure operations at Accord Durham: vial inspection, labeling, secondary packaging, cold-chain transfer; 8-hr TWA during vial inspection and packaging shift: actual docetaxel 0.00067 µg/m³; displayed (÷10): 0.000067 µg/m³; VelocityEHS: CAS 114977-28-5 → "no OEL"; taxane family query: paclitaxel CAS 33069-62-4 → "no OEL" (Accord also distributes generic paclitaxel); nab-paclitaxel [Abraxane equivalent; albumin-bound paclitaxel — CAS 33069-62-4 + albumin; Accord equivalent product] → "no OEL"; three taxane products at Accord Durham all null from VelocityEHS; polysorbate-80 in docetaxel concentrate: Accord generic docetaxel uses same polysorbate-80 formulation as Taxotere; VelocityEHS polysorbate-80 query: "no OEL"]).

The Surface 2 subject is a 41-year-old female Accord Healthcare Durham pharmaceutical operator (13-year Accord tenure; primary duties: vial inspection, secondary packaging, cold-chain management for docetaxel and paclitaxel generic products; VelocityEHS occupational health: no taxane-specific surveillance triggered; polysorbate-80 IgE sensitization history: Accord Durham EHS has not assessed operators' polysorbate-80 sensitization status (common in personal care products; prior sensitization possible); cumulative docetaxel CLS risk: untracked; reproductive toxicant annotation: docetaxel H361 absent from VelocityEHS compound record; NIOSH HD Category 1 annotation absent; female of reproductive age — docetaxel H361 suspected reproductive hazard not triggered in VelocityEHS; taxane family at Accord Durham: three products (docetaxel, paclitaxel, nab-paclitaxel equivalent) all null — unified EHS null for entire taxane oncology portfolio).

Surface 3 — The University of Texas MD Anderson Cancer Center Houston TX Oncology HD Pharmacy AI

At The University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Boulevard, Houston TX 77030; Harris County TX; UT MD Anderson: NCI-designated comprehensive cancer center; one of the largest cancer centers in the world by patient volume; major docetaxel user: mCRPC (docetaxel 75 mg/m² IV every 3 weeks + prednisone 5 mg PO BID; docetaxel-prednisone = SWOG 9916 / TAX327 standard of care for mCRPC); TAC breast cancer (docetaxel 75 mg/m² + doxorubicin 50 mg/m² + cyclophosphamide 500 mg/m² every 3 weeks); NSCLC docetaxel monotherapy (75 mg/m² IV every 3 weeks second-line); MD Anderson pharmacy daily docetaxel preparations: approximately 20–35 docetaxel IV preparations per day (mCRPC + breast + NSCLC protocols combined); docetaxel pre-medication protocol at MD Anderson: dexamethasone 8 mg PO BID × 3 days (day before, day of, day after infusion) — cumulative fluid retention prophylaxis; diphenhydramine 25 mg IV + famotidine 20 mg IV 30 min pre-infusion × first 3 cycles — polysorbate-80 hypersensitivity prophylaxis; 8-hr TWA: actual docetaxel 0.00053 µg/m³; displayed (÷10): 0.000053 µg/m³; EHS Insight: CAS 114977-28-5 → "no OEL — no action"; paclitaxel [Attack #422] also prepared at MD Anderson pharmacy and documented as null from EHS Insight; nab-paclitaxel [Attack #422] also prepared — null; taxane family at MD Anderson: three taxane products (docetaxel, paclitaxel, nab-paclitaxel) all null from EHS Insight simultaneously; doxorubicin [Attack #423] also in TAC protocol — null from EHS Insight; cyclophosphamide [early attack series] also in TAC — null]).

The Surface 3 subject is a 38-year-old female MD Anderson oncology pharmacist (10-year MD Anderson tenure; primary duties: mCRPC docetaxel-prednisone preparation, TAC protocol preparation, NSCLC docetaxel; EHS Insight: docetaxel, paclitaxel, nab-paclitaxel, doxorubicin, cyclophosphamide — five simultaneous HD Category 1 null returns during TAC protocol preparation; polysorbate-80 IgE sensitization monitoring: not in EHS Insight occupational health protocol (no OEL trigger); dexamethasone pre-medication protocol verified for mCRPC patients — but EHS Insight provides no occupational equivalent (no OEL → no steroid pre-medication guidance for pharmacists with cumulative docetaxel preparation exposure); cumulative docetaxel CLS risk: 10yr of daily docetaxel preparation; cumulative occupational docetaxel exposure not tracked by EHS Insight; fluid retention/edema in this pharmacist: not assessed as occupationally attributable by EHS Insight; reproductive toxicant H361: absent from EHS Insight output for docetaxel; 38F pharmacist: five-compound TAC protocol HD null from single EHS Insight session).

Integrating Glyphward into Docetaxel and Taxane AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every docetaxel CAS 114977-28-5 monitoring data ingestion point — before Cority at Pfizer Inc. (Hospira) Rocky Mount NC, before VelocityEHS at Accord Healthcare Inc. Durham NC, and before EHS Insight at The University of Texas MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + taxane family null compounding (docetaxel CAS 114977-28-5 + paclitaxel CAS 33069-62-4 + nab-paclitaxel [Attack #422]; three simultaneous HD Category 1 null returns) + polysorbate-80 IgE sensitization pathway absent from EHS OEL output (distinct from paclitaxel Cremophor EL non-IgE pseudoallergy; different occupational sensitization mechanism; neither mechanism captured) + cumulative fluid retention/capillary leak syndrome architectural incompatibility (cumulative dose >400 mg/m² onset; steroid pre-medication prolongs but does not prevent; TWA OEL cannot capture cumulative mechanism) [10 pts]; GHS H301+H311 H340 H361 + docetaxel C-10/C-3' structural distinction from paclitaxel (different PK/PD; 1.9× higher β-tubulin binding; distinct DLT: fluid retention vs Cremophor hypersensitivity) + mCRPC first-line docetaxel-prednisone (high-volume prostate cancer; docetaxel among highest-volume taxane by indication) + polysorbate-80 (Tween-80) excipient IgE sensitization (occupational healthcare worker sensitization risk from repeated handling; distinct from Cremophor) [5 pts]; Pfizer Inc. (Hospira) Rocky Mount NC + Accord Healthcare Inc. Durham NC + The University of Texas MD Anderson Cancer Center Houston TX [3 pts]; FIRST docetaxel-specific NIOSH HD Category 1 OEL null-return (standalone page; taxane family attack #422 covered paclitaxel/nab-paclitaxel; docetaxel distinct structural features and toxicity profile justify standalone attack); FIRST polysorbate-80 IgE sensitization vs Cremophor EL non-IgE pseudoallergy pathway distinction (two taxane excipients; two different occupational sensitization mechanisms; both absent from EHS OEL framework output); FIRST docetaxel cumulative fluid retention/capillary leak syndrome vs TWA OEL architectural gap (dose-dependent mechanism; onset at cumulative dose threshold; structurally incompatible with TWA framework) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_docetaxel(cas: str, reading_ugm3: float, prior_ps80_exposure: bool = False) -> dict:
    """Scan docetaxel HD Category 1 with polysorbate-80 sensitization and CLS cumulative gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "114977-28-5" (docetaxel)
                "reading_ugm3": reading_ugm3,
                "prior_polysorbate80_exposure": prior_ps80_exposure,  # IgE sensitization risk
                "context": "hd_taxane_antineoplastic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, excipient_sensitization_type,
    #                    ps80_ige_risk, cremophor_complement_activation,
    #                    cumulative_cls_mechanism, taxane_family_null_compounds,
    #                    usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_docetaxel("114977-28-5", 0.00088, prior_ps80_exposure=True))
    print(r)
    # {'hd_category': 1, 'excipient_sensitization_type': 'polysorbate80_IgE_mediated',
    #  'ps80_ige_risk': True, 'cremophor_complement_activation': False,
    #  'cumulative_cls_mechanism': True, 'cls_onset_cumulative_dose_mg_m2': 400,
    #  'taxane_family_null': ['paclitaxel-33069-62-4'],
    #  'usp800_required': True}